United States: Flawed Valuation Leads Delaware Court To Award Damages To Option Holders

On July 28, 2015, the Delaware Court of Chancery issued a post-trial opinion in which it criticized in particularly strong terms the analysis performed by a financial firm that was retained to value companies that were being sold to a third party or spun off to stockholders (the "valuation firm").  See Fox v. CDX Holdings Inc., C.A. No. 8031-VCL (Del Ch. July 28, 2015).  CDX is just the latest decision in which the Chancery Court has awarded damages and/or ordered injunctive relief based in part on a financial firm's failure to discharge its role appropriately.  Calling the valuation firm's work "a new low," Vice Chancellor Laster's opinion is another chapter in this cautionary tale that lays bare how financial firms can be exposed not only to potential monetary liability but, as importantly, significant reputational harm from flawed sell side work on M&A transactions. 


The action involved the sale or spin-off of the businesses of Caris Life Sciences, Inc. ("Caris"), a privately-held Delaware corporation that operated through three subsidiaries: Caris Diagnostics, TargetNow and Carisome.  Caris' founder, David Halbert, owned 70.4% of its outstanding equity and an investment fund, JH Whitney VI, L.P., owned 26.7%.  To secure financing for TargetNow and Carisome, Caris sold Caris Diagnostics to Miraca Holdings, Inc in the fall of 2011.  To minimize taxes, the transaction was structured as a "spin merge," whereby Caris transferred ownership of TargetNow and Carisome to a new subsidiary, which it then spun off to stockholders.  At that point, Caris (owning only Caris Diagnostics) merged into a subsidiary of Miraca.

Most of the equity in Caris not owned by Halbert or JH Whitney (2.9%) consisted of stock options that were cancelled in connection with the Miraca transaction, with each holder having the right to receive for each covered share the amount by which the "Fair Market Value" of the share exceeded the option exercise price.  Option holders brought suit challenging, among other things, the value attributed to TargetNow ($47 million) and Carisome ($18 million) for purposes of determining Fair Market Value.  Caris' tax advisor initially arrived at these valuations, and the valuation firm (which was retained at the buyer's insistence) then supposedly independently arrived at the same results.  Based in part on myriad problems with the financial projections and analyses underlying the valuation firm's work, the Court found that Caris breached its contract with option holders; determined that the value of TargetNow and Carisome combined was approximately $300 million; and awarded damages of approximately $16 million to the option holders' for their interest. 

Takeaways and Analysis

1.  The Court repeatedly criticized as results-driven the analyses performed by Caris' valuation firm regarding TargetNow and Carisome.  Contrasting the work performed on the transaction with contemporaneous emails and financial analyses from this same firm, the Court found that Caris' valuation advisor manipulated downward its valuation of TargetNow and Carisome to achieve a desired zero-tax outcome at the corporate level for the spin-off of TargetNow and Carisome, thereby fatally undermining the credibility of its work. 

For instance, for purposes of the challenged transaction, TargetNow was valued at $47.23 million.  Three years earlier, however, Caris paid $40 million for TargetNow when it was generating only $1 million in annual revenue.  By the time of the Miraca transaction, revenue had increased 5,000% to approximately $50 million, yet the valuation firm and management were suggesting that the Court accept a valuation reflecting an increase in value of only 17%.  Likewise, "ordinary course" asset impairment analyses valued TargetNow's trade name and clinical database alone at $104 million excluding debt.  Similarly, JH Whitney, a "sophisticated private equity firm," gave a presentation to the fund's advisory board valuing its 26.7% stake in TargetNow at $41 million, implying a $153 million valuation for the company.

The situation with Carisome, valued for purposes of the spin at $17.79 million, was no different.  The Court found that the "major purpose' of the entire Miraca transaction was to provide ongoing funding for Carisome, and the controlling stockholders invested $100 million of the proceeds of the sale to fund that company, reflecting confidence in its prospects.  In addition, the valuation firm's stock option analyses for Caris only months earlier valued Carisome at between $116 and $199 million.  This and similar evidence fundamentally undermined the $17.79 million valuation. 

2.  The Court had many issues with the valuation firm's analyses.  Among other things, the Court found that the valuation firm: (i) did not perform a comparable companies analysis even though only months before, during its "ordinary course" work, it deemed another transaction in fact to be comparable (and that transaction implied a significantly higher valuation for TargetNow but such a valuation would have frustrated the goal of a tax-free spin-off); (ii) reached the same valuation for Carisome as the tax advisor despite using materially different inputs in its analysis, such that the "only possible explanation" was that the valuation firm "did not prepare its table independently"; (iii) simply copied the tax advisor's report, doing so blatantly such that "the output matched . . . even when the inputs differed"; (iv) used for its analysis "the cost method" and rejected other valuation methods, all of which "conflicted with all of its prior valuations"; (v) for the spin-off opined that it is not possible to accurately forecast cash flows notwithstanding that its ordinary course analyses "relied on management projections and used" discounted cash flow analyses based on those projections; (vi) "made significant errors," including mistakenly using a company's trailing nine-month revenue for 2010 instead of projected twelve-month revenue for 2011;  (vii) based its valuation on the tax advisor's work, which did not determine the common stock's fair market value, but instead was intended to determine intercompany transfer tax liability – as a result, certain assets were excluded, including goodwill. 

Taken together (and perhaps in some instances individually), these issues led the Court to conclude that the valuation firm's analyses were "so flawed as to support both an inference of bad faith and a finding the process was arbitrary and capricious."  The Court characterized it as a "new low" in terms of situations leading to decisions criticizing erroneous or outcome-oriented analyses. 

In a variety of contexts, the Delaware Chancery Court has seized on evidence that advisors are manipulating their analyses to support an outcome desired by a seller's management or board to discount or completely disregard the advisors' work.  See LongPath Capital, LLC v. Ramtron Int'l Corp., C.A. No. 8094-VCP (Del. Ch. June 30, 2015); Merlin Partners LP v. AutoInfo, Inc., C.A. No. 8509-VCN (Del. Ch. Apr. 30, 2015); In re: El Paso Pipeline Partners, L.P. Deriv. Litig., C.A. No. 7141-VCL (Del. Ch. Apr. 20, 2015); In re Rural/Metro Corp. S'holders Litig., C.A. No. 6350-VCL (Del. Ch. Oct. 10, 2014); Chen v. Howard-Anderson, C.A. No. 5878-VCL (Del Ch. April 8, 2014); In re Orchard Enter., Inc. S'holder Litig., C.A. No. 7840-VCL (Del. Ch. Feb. 28, 2014). 

Analyses performed in the ordinary course of business or on a "clear day" typically will be afforded significantly more weight than analyses based on different methodologies prepared in connection with a particular transaction or for litigation.  It also is difficult to overstate the importance a court will attach to contemporaneous emails and analyses, particularly when they conflict with work performed to achieve a desired outcome or for litigation.  The Chancery Court has made clear in this series of decisions its view that outside financial firms must maintain the integrity and credibility of their work and their own independence in order for their efforts to provide any support to a transaction that is subject to challenge.    

3.  The Court's analysis of witness credibility is noteworthy. 

With respect to the controller and CFO, the Court observed that they admitted having "engaged in fraud" with respect to Miraca.  The controller testified, for instance, that the projections provided to the buyer were a "fantasy land," "an impossibility," and "intentionally exaggerated."  He made these statements in order to persuade the Court not to credit those projections over the ones supporting the valuation firm's lower valuations leading to a zero-tax outcome.  But the Court recognized that, by so testifying, the controller and CFO "entangled themselves in a double liar problem.  They asked me to believe them now that they were lying then. . . ."  To the Court, they had a fundamental "credibility problem: their willingness to say what they believed would help them in this litigation, regardless of whether it is actually true."  The Court therefore did not credit their testimony even though it also found that neither was "inherently bad or malicious.  Like all of us, they are multidimensional. . . .  But humans respond to incentives, and powerful incentives can lead humans to cross lines they otherwise would respect."

The Court also pointed out that, except for the controller and CFO, the defense witnesses seemed honestly to believe that TargetNow and Carisome had "very little value in fall 2011."  The Court attributed this testimony to "hindsight bias" produced by actual results following the Miraca transaction – Target Now did not reach profitability and Carisome did not develop a marketable product.  The defense witnesses "testified with conviction that they believed these things in the fall of 2011, but the contemporaneous evidence showed they did not."  To the Court, the "bias results from the fact that those who know the outcome cannot ignore that knowledge as they try to perform an objective evaluation of the" prior situation. 

The Court's references to the "double liar" problem and "hindsight bias" in discounting witness testimony, while at the same time either refusing to vilify those witnesses (in the cases of the controller and CFO) or concluding that the witnesses were testifying honestly but inaccurately (in the case of other company witnesses), reflects a nuanced approach to assessing the credibility of witnesses.  And that credibility is just as important as supportive contemporaneous documentary evidence.  It goes without saying that a court's conclusion that a witness is not credible could prove as damaging as contradictory contemporaneous documents.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.